Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson's disease
Researchers conducted a double-blind, randomised trial on more than 190 people suffering from Parkinson's disease.
Half of the participants received a weekly injection of two milligrams of the drug exenatide, which is a GLP-1 receptor agonist similar to medicines such as Ozempic or Wegovy.
The other half of the study participants received a placebo.
At the end of the trial, the researchers found no improvement in symptoms or brain imaging after 96 weeks of treatment, according to the study's findings published in The Lancet.
'The results of this trial have been eagerly anticipated, and the negative results will be a major disappointment to patients affected by Parkinson's disease and the Parkinson's disease research community,' Thomas Foltynie, a professor at University College London (UCL) and the study's lead author, said in a statement.
'It is not yet clear whether there may be a subgroup of people with Parkinson's disease who may get benefit from the use of exenatide,' he added.
He said that there will be more research to see if for example, people with 'pre-diabetes' might 'predict a better response to exenatide'.
Exploring the potential of weight-loss drugs
Previous small trials have suggested that these medications could have potential benefits for people with Parkinson's disease.
Exenatide, marketed as Byetta, is mainly used to help people with Type 2 diabetes manage blood sugar levels, according to the European Medicines Agency.
These drugs work by enhancing insulin secretion and slowing digestion, which can reduce food intake and appetite.
Exenatide was the first GLP-1 drug approved by US regulators for treating diabetes in 2005. This class of drugs is now also used in some cases to treat obesity.
Trials have also looked at their potential to help patients with a wide range of conditions ranging from heart disease to opioid overdose and alcohol intoxication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
6 days ago
- Euronews
Novo Nordisk shares plummet over 20% on weight-loss drug sale slump
Novo Nordisk shares fell by over 20% on Tuesday after the firm slashed its full-year guidance, blaming weaker US sales expectations for its obesity drug Wegovy and Ozempic diabetes treatment. In the wake of the sell-off, the pharma giant said long-time employee Maziar Mike Doustdar would take over as president and CEO, replacing Lars Fruergaard Jørgensen — who unexpectedly stepped down in May. Doustdar, the first non-Dane to lead the company, will take over on 7 August. Novo cut its financial guidance for the year on Tuesday, expecting yearly sales to grow by 8% to 14%, compared to a previous forecast of up to 21%. Operating profit is now expected to grow 10% to 16%, compared to a previously predicted upper limit of 24%. Depressed sales expectations for Wegovy and Ozempic are linked to rival products from drug maker Eli Lilly, as well as other, cheaper dupes of the pharmaceuticals. 'For Wegovy in the US, the sales outlook reflects the persistent use of compounded (drugs), slower-than-expected market expansion and competition,' said Novo. The firm's sales rose 18% in constant currencies in the first six months of the year, while operating profit was up 29%. In 2024, Wegovy's popularity helped Novo to become Europe's most valuable listed company, but its value has since plummeted. The company previously downgraded its outlook in May due to intensifying competition in the weight-loss drug markets. Novo is due to report its full second-quarter sales on 6 August.
Euronews
25-07-2025
- Euronews
Iran sends telecom satellite Nahid-2 into orbit on Russian rocket
An Iranian communications satellite was sent into orbit aboard a Russian rocket on Friday, a launch that highlighted strong ties between the two countries. The Soyuz rocket lifted off as scheduled from Vostochny launchpad in far eastern Russia. It carried two Russian Ionosphere-M Earth observation satellites, along with Iran's Nahid-2 satellite and 17 smaller Russian satellites, and put them into designated orbits. "The operational life of the NAHID-2 satellite is planned for two years," said Hassan Salariyeh, head of the Iranian Space Agency. "Typically, satellites have a lifetime of five years at low altitude (LEO) and 10 years at high altitude (GEO)." Russia, which signed a 'strategic partnership' treaty with Iran in January, strongly condemned the Israeli and US strikes on Iran last month. Russian President Vladimir Putin has suggested that Moscow could help negotiate a settlement that could allow Tehran to pursue a peaceful atomic programme while assuaging Israeli security concerns. At the same time, Putin has emphasised that Tehran hasn't asked Moscow for military assistance and noted that the partnership treaty doesn't envision such aid. Russia has maintained a delicate balancing act in the Middle East for decades, trying to maintain warm relations with Israel even as it developed strong economic and military ties with Iran. Friday's launch was announced before nuclear talks between Iran and Britain, France, and Germany began in Istanbul and comes after Tehran tested one of its satellite-carrying rockets with a suborbital flight on Monday. Iran-Russia space cooperation The launch of Nahid 2 was a continuation of Iran and Russia's cooperation on ventures into space. In November, Russia launched a pair of Iranian satellites named Kowsar and Hodhod, the first launched on behalf of the country's private sector. It followed two previous Russian launches of Iranian satellites in 2022 and 2024. The Nahid series of satellites (1 and 2) was designed and built by the Iranian Space Agency for telecommunication missions at the Iranian Space Research Institute. According to the Iranian space agency, the satellite provides the power it needs using solar arrays on the hull. Development of the Nahid 2 continued, despite delays in the launch of the Nahid 1 satellite due to technical problems and international coordination. To complement the performance of the NAHID-1 satellite, four stations were built in different parts of the country. NAHID-1 was originally supposed to be deployed with the Sefir-1 satellite in the summer of 2018 to orbit at 250 to 375 km, but a technical incident before the launch of the Ambassador caused the mission to be cancelled. The Iranian Space Agency has announced that plans for the Nahid 3 project, which it describes as a more advanced, are under way. Iran has been sending satellites to orbit in what Western analysts see as efforts to boost its aerospace programme. These projects are in line with Iran's plans for self-sufficiency in space technology and the development of commercial and research applications, according to the Iranian Space Agency.
France 24
25-07-2025
- France 24
Russian rocket puts Iran satellite into space: Iran media
"The Nahid-2 communications satellite was launched from Russia's Vostochny Cosmodrome using a Soyuz rocket," state television said. Weighing 110 kilograms (over 240 pounds), the satellite was designed and manufactured by Iranian engineers, the broadcaster added. Western governments have long expressed concern that technological advances made in Iran's space programme can also be used to upgrade its ballistic missile arsenal. The launch was announced shortly before nuclear talks between Iran and Britain, France and Germany opened in Istanbul. In December, Iran announced it had put its heaviest payload to date into space, using a domestically manufactured satellite carrier. In September, Iran said it had put the Chamran-1 research satellite into orbit using the Ghaem-100 carrier, which is produced by the Revolutionary Guards' aerospace division.
